
News|Articles|July 1, 2012
Pipeline Preview
Recent FDA action (through June 2012) related to, Darunavir, Prezista, Janssen Therapeutics, Ridaforolimus, Merck, Tafamidis meglumine, Pfizer, mechlorethamine, Ceptaris Therapeutics, AVP-923, Avanir Pharmaceuticals, NKTR-181, Nektar Therapeutics, EDI200, Edimer Pharmaceuticals, Galeterone, TOK-001, Tokai Pharmaceuticals, Butoconazole nitrate 2% vaginal cream, Gynazole-1, Perrigo
Advertisement
Complete response
Priority review
Fast-track designation
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
HaVy Ngo-Hamilton, Pharm.D. | 2026 MHE Emerging Leaders in Healthcare
2
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2026
3
FDA clears Amneal’s ready-to-use romidepsin, filling gap left by Teva’s withdrawal
4
Sham Firdausi, M.P.H., M.Sc., MBA | 2026 MHE Emerging Leaders in Healthcare
5

























